Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $320

Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $320

Morgan Stanley analyst Cecilia Furlong maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $300 to $320.

byBenzinga Newsdesk

January 6, 2023

1 minute read

Morgan Stanley analyst Cecilia Furlong maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $300 to $320.

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday

By Lisa Levin

March 1, 11:18 AM

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

AMPH

Amazon Takes On Microsoft And Google With James Bond-Inspired AI Chatbot ‘Q’

By Benzinga Neuro

November 29, 7:25 AM

Q is currently available in a preview version, with several features accessible free of charge.

AMZN

Plug Power +64% After Securing $1.66B Loan Guarantee From Biden Administration

By Nabaparna Bhattacharya

May 14, 9:26 AM

Plug Power skyrockets by over 64% following a $1.66B Loan Guarantee from the Biden Administration for green hydrogen production, driving industrial decarbonization efforts.

PLUG

Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings

By Vandana Singh

Today, 11:15 AM

Bristol Myers Squibb & Co (NYSE: BMY) announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage IIA to IIIB non-

BMY

Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $320

Related Posts

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday

Amazon Takes On Microsoft And Google With James Bond-Inspired AI Chatbot ‘Q’

Plug Power +64% After Securing $1.66B Loan Guarantee From Biden Administration

Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings